摘要
本研究对益生菌菌株副干酪乳杆菌L9(Lactobacillus paracasei L9)进行了体外及体内的安全性评价。利用体外试验评价了L9的抗生素抗敏感性及生物胺的生成能力;体内试验评价了L9的经口毒性、正常状况下的易位风险及腹腔注射模拟的极端情况下的易位风险。结果表明,菌株L9不存在种属特有耐性以外的抗生素耐受性,不存在抗生素转移的风险;在脱羧酶培养基中培养未发现生物胺的产生;以108、109、1010 cfu/鼠灌胃28d,小鼠未发生不良反应,未发生向血液、肝脏、脾脏和肾脏的易位;109cfu/鼠腹腔注射发生易位现象,但未发生菌血症并且易位不会造成疾病或导致死亡,同时易位状况随时间有所缓解,表现为较高的易位安全性。试验结果证实副干酪乳杆菌L9具有较高安全性,可以直接应用于工业化生产。
The safety ofLactobacillus paracasei L9 was evaluated. In our invitro study, the antibiotic resistance and the ability to produce biogenic amine were determined. That this strain did not possess transferable antibiotics resistance, and it did not produce biogenic amine. The oral toxicity of this strain was evaluated in Balb/C mice. Oral administration of the strain had no adverse effects on mouse body weight and that there was no treatment-associated bacterial translocation. In trapertoneal administration caused a signiifcant translocation to liver, spleen and kidney. However, this translocation did not cause illness or death throughout the experiment. The results showed that L.paracaseiL9 is likely to be safe for human consumption.
出处
《中国奶牛》
2015年第21期27-31,共5页
China Dairy Cattle
基金
中央在京高校重大成果转化项目"益生菌生产关键技术科技成果转化"
南方大城市奶牛健康养殖生产技术集成及产业化示范(2012BAD12B08)
关键词
副干酪乳杆菌
L9
安全性
抗生素耐性
易位
Lactobacillus paracaseiL9
Safety evaluation
Antibiotic resistance
Bacterial translocation
